-39.3%
CPRT vs MRNA
+159.5%
-198.9%
-58.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.3% | -3.2% | -2.0% |
| 7D | -3.6% | -13.8% | +10.3% | -3.0% |
| 30D | +10.9% | -17.7% | +28.5% | +11.5% |
| 3M | -8.8% | +14.3% | -23.1% | -9.9% |
| 6M | -6.8% | +336.0% | -342.8% | -15.8% |
| YTD | -21.2% | +575.9% | -597.1% | -30.4% |
| 1Y | -25.4% | +724.4% | -749.8% | -34.8% |
| All | -39.3% | +159.5% | -198.9% | -44.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling